Recruiting

Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function

The investigators will measure blood levels of 1,5-anhydroglucitol in obese children with or without type 2 diabetes and correlate them with parameters related to functional beta-cell mass and glucose metabolism. The values will be compared to those obtained in healthy volunteers. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in children with obesity with or without type 2 diabetes.

I'm interested View official listing

ClinicalTrials.gov IDNCT06682481

PhaseNot Applicable

Enrollment50

SponsorPhilippe Klee, MD-PhD

Age12 Years – 16 Years

SexALL

I'm interested View official listing

Conditions studied

Obesity, Childhood, Type 2 Diabetes Mellitus in Obese

About this study

Interventions

Other: Measurement of biomarker — Measurement of blood levels of 1,5-anhydroglucitol

Primary outcomes

Correlation of 1,5-anhydroglucitol levels in obese children with indirect markers of beta-cell function and mass and with metabolic control (First oral glucose tolerance test)
Correlation of 1,5-anhydroglucitol levels in obese children with indirect markers of beta-cell function and mass and with metabolic control (Second oral glucose tolerance test, 2 years after the first)

Eligibility information

Inclusion Criteria: * Children aged 12 to 16 years * Obesity. Defined as a body-mass index above the 97th percentile. * Ability to give informed consent as documented by signature Exclusion Criteria: * Patients with diabetes mellitus and positive autoantibodies against islets, insulin, islet antigen 2, glutamic acid decarboxylase or Zinc transporter 8. * Patients with known liver disease (other than NAFLD) * Patients treated with an oral antidiabetic drug, glucagon-like peptide-1 analogues or insulin at the time of or less than 2 weeks prior to inclusion. * Patients treated with a drug known to affect liver function

Study locations

University Hospital of Geneva, Geneva, Canton of Geneva 1211 Switzerland

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-04.